Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:

A GRI (Glucose Responsive Insulin) for Better Treatment of Type 1 Diabetes

STATUS: Awarded
POSTED: Sep 06 2011
SOURCE: InnoCentive

This Challenge, sponsored by the Juvenile Diabetes Research Foundation International (JDRF) (the Seeker), is looking for novel ideas for the development of “glucose-responsive insulin”, an insulin that would work only when the body needs it, and deliver the precise amount of insulin activity in response to circulating glucose levels to control and maintain normal blood glucose levels throughout a daily routine with once-daily or less frequent dosing in people with insulin-dependent diabetes. JDRF envisions that the Winning Solution (or Solutions) from this Challenge will be further developed in a second phase that may involve the Winning Solvers and potentially partners from the commercial sector.

This Challenge requires only a written proposal from the Applicant (Solver).



Challenge ID: 9932818
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Challenge Overview

This Challenge sponsored by the Juvenile Diabetes Research Foundation International (JDRF) is looking for novel, breakthrough ideas for the design of a modified insulin or insulin plus matrix that would allow for tightly regulated internal delivery of physiologically relevant doses in response to local glucose concentrations in diabetes, i.e. a “glucose-responsive insulin”.  Please note that a complex electronic device does not fit this challenge. 

JDRF envisions that the Winning Solution (or Solutions) from this Challenge will be further developed in a second phase (“Pre-Clinical Proof-of Principle Validation” phase) to reduce the idea into practice, such as, but not limited to, preclinical discovery and development toward a proof-of-concept, and may involve the Winning Solvers as part of a larger project team that may involve commercial partners. 

This is a Theoretical Challenge that requires only a written proposal to be submitted.  The Challenge award will be contingent upon theoretical evaluation of the proposal by JDRF.  JDRF envisions that up to four (4) awards will be awarded to solutions meeting all or most of the Challenge requirements, up to a total award amount of $100,000.  The review and award decisions will be made by JDRF in consultation with a jury panel comprised of international experts.  

To receive an award, the Solvers will have to transfer to JDRF their exclusive Intellectual Property (IP) rights to the solution.  

Additional information about Type 1 Diabetes & Glucose-Responsive Insulin can be found in the GRI Prize Primer at the link -



What is InnoCentive?

InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical IP Transfer Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge
Challenge Referral Program
Earn $10,000 USD for referring the winner of this Challenge!
InnoCentive Trust Partners